fluticasone furoate; vilanterol trifenatate - Profile

What are the generic drug sources for fluticasone furoate; vilanterol trifenatate and what is the scope of freedom to operate?

Fluticasone furoate; vilanterol trifenatate is the generic ingredient in one branded drug marketed by Glaxo Grp Ltd and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Fluticasone furoate; vilanterol trifenatate has one hundred and thirty-five patent family members in twenty-nine countries.

Summary for fluticasone furoate; vilanterol trifenatate

International Patents:	135
US Patents:	4
Tradenames:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for fluticasone furoate; vilanterol trifenatate

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for fluticasone furoate; vilanterol trifenatate

Dosage:

POWDER;INHALATION

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Paragraph IV (Patent) Challenges for FLUTICASONE FUROATE; VILANTEROL TRIFENATATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
BREO ELLIPTA	Powder for Inhalation	fluticasone furoate; vilanterol trifenatate	100 mcg/25 mcg	204275	1	2025-06-16

US Patents and Regulatory Information for fluticasone furoate; vilanterol trifenatate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxo Grp Ltd	BREO ELLIPTA	fluticasone furoate; vilanterol trifenatate	POWDER;INHALATION	204275-003	May 12, 2023		RX	Yes	Yes					Y
Glaxo Grp Ltd	BREO ELLIPTA	fluticasone furoate; vilanterol trifenatate	POWDER;INHALATION	204275-003	May 12, 2023		RX	Yes	Yes					Y
Glaxo Grp Ltd	BREO ELLIPTA	fluticasone furoate; vilanterol trifenatate	POWDER;INHALATION	204275-003	May 12, 2023		RX	Yes	Yes					Y
Glaxo Grp Ltd	BREO ELLIPTA	fluticasone furoate; vilanterol trifenatate	POWDER;INHALATION	204275-003	May 12, 2023		RX	Yes	Yes					Y
Glaxo Grp Ltd	BREO ELLIPTA	fluticasone furoate; vilanterol trifenatate	POWDER;INHALATION	204275-003	May 12, 2023		RX	Yes	Yes

Expired US Patents for fluticasone furoate; vilanterol trifenatate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Glaxo Grp Ltd	BREO ELLIPTA	fluticasone furoate; vilanterol trifenatate	POWDER;INHALATION	204275-001	May 10, 2013
Glaxo Grp Ltd	BREO ELLIPTA	fluticasone furoate; vilanterol trifenatate	POWDER;INHALATION	204275-002	Apr 30, 2015
Glaxo Grp Ltd	BREO ELLIPTA	fluticasone furoate; vilanterol trifenatate	POWDER;INHALATION	204275-001	May 10, 2013
Glaxo Grp Ltd	BREO ELLIPTA	fluticasone furoate; vilanterol trifenatate	POWDER;INHALATION	204275-002	Apr 30, 2015
Glaxo Grp Ltd	BREO ELLIPTA	fluticasone furoate; vilanterol trifenatate	POWDER;INHALATION	204275-002	Apr 30, 2015

International Patents for fluticasone furoate; vilanterol trifenatate

Country	Patent Number	Title	Estimated Expiration
Taiwan	I455735
Australia	2006273856	Medicament dispenser
Taiwan	200730207
Hong Kong	1072206
Poland	3578169

Supplementary Protection Certificates for fluticasone furoate; vilanterol trifenatate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2506844	LUC00077	Luxembourg		PRODUCT NAME: PRODUIT DE COMBINAISON PHARMACEUTIQUE COMPRENANT UN SEL PHARMACEUTIQUEMENT ACCEPTABLE D'UMECLIDINIUM (PAR EXEMPLE LE BROMURE D'UMECLIDINIUM), LE VILANTEROL OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE (PAR EXEMPLE LE TRIFENATATE DE VILANTEROL) ET LE FUROATE DE FLUTICASONE; AUTHORISATION NUMBER AND DATE: EU/1/17/1236 20171117
1305329	08C0014	France		PRODUCT NAME: FLUTICASONE FUROATE; REGISTRATION NO/DATE: EU/1/07/434/001 20080111
1519731	132013902182575	Italy		PRODUCT NAME: AZELASTINA CLORIDRATO/FLUTICASONE PROPIONATO(DYMISTA); AUTHORISATION NUMBER(S) AND DATE(S): 2011/07125-REG, 20111024;041808015/M-027/M-039/M-041/M, 20130527
1519731	13C0067	France		PRODUCT NAME: AZELASTINE OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE; NAT. REGISTRATION NO/DATE: NL41755 20130925; FIRST REGISTRATION: SK - 24/0055/13-S 20130215
2506844	132018000000341	Italy		PRODUCT NAME: UN PRODOTTO DI COMBINAZIONE FARMACEUTICA COMPRENDENTE UN SALE FARMACEUTICAMENTE ACCETTABILE DI UMECLIDINIO (AD ESEMPIO BROMURO DI UMECLIDINIO), VILANTEROLO O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE (AD ESEMPIO VILANTEROLO TRIFENATATO) E UN FUROATO(TRELEGY ELLIPTA - FLUTICASONE FUROATO/UMECLIDINIO/VILANTEROLO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1236, 20171117

Investment Scenario, Market Dynamics, and Financial Trajectory for Fluticasone Furoate / Vilanterol Trifenatate

Last updated: February 3, 2026

Summary

This report details the investment potential, market landscape, and financial projections for the combination inhaler drug Fluticasone Furoate (FF) and Vilanterol Trifenatate (VI), marketed as Relvar Ellipta and Trelegy Ellipta. As a respiratory medication approved for asthma and COPD, this drug combination exhibits significant growth prospects driven by rising respiratory disease prevalence, favorable regulatory environments, and strategic patent protections. This analysis synthesizes current market data, competitive positioning, patent exclusivities, and forecasted sales trajectories to inform investment decisions.

---

1. Pharmacological Profile and Regulatory Status

Component	Pharmacology	Approved Indications	Regulatory Milestones	Patent Status	Key Agencies
Fluticasone Furoate	Inhaled corticosteroid (ICS)	Asthma, COPD	FDA (2013), EMA (2014)	Extended patent through 2028, with follow-up formulations	FDA, EMA, PMDA
Vilanterol Trifenatate	Long-acting β2-agonist (LABA)	Asthma, COPD	Same as above	Patent protection until at least 2027	FDA, EMA
Combination (FF/VI)	Fixed-dose inhaler	Asthma, COPD	Approved in US (2014, 2016), Europe (2014), Japan (2014)	Extended patent strategy with formulation patents	FDA, EMA, PMDA

Note: The combination’s patent life is critical for market exclusivity and influences investment outlook.

---

2. Market Dynamics

2.1 Global Respiratory Disease Market Overview

Segment	Market Size (USD billion, 2022)	CAGR (2018-2028)	Key Drivers	Major Markets
Asthma	20.5	4.0%	Rising prevalence, underdiagnosis	US, Europe, Asia-Pacific
COPD	46.8	4.5%	Increased smoking, aging populace	US, Europe, China, Japan

2.2 Key Market Players

Company	Key Drugs	Market Share (%)	Notable Patents	Strategic Moves
GSK	Advair, Trelegy Ellipta	35% (combined inhalers)	Expiring 2024-2028	Patent extension strategies, pipeline expansion
AstraZeneca	Symbicort, Breztri	25%	Patents until 2029	Device innovation, new formulations
Boehringer Ingelheim	Spiriva	10%	Patent expiring 2025	Generics entry anticipated
Others	Various	30%	-	Generic and biosimilar entry

The FF/VI combination holds approximately 10% market share in the inhaler segment but is gaining dominance due to its efficacy and once-daily dosing.

2.3 Growth Drivers & Constraints

Drivers	Constraints
Rising prevalence of asthma and COPD	Patent cliffs for key competitors
Improved disease management protocols	Price pressures in mature markets
Increased adoption of inhaler devices	Competition from biologics in severe cases
Aging global population	Regulatory hurdles for new formulations

---

3. Financial Trajectory and Market Penetration Forecasts

3.1 Historical Sales Data

Year	Global Sales (USD millions)	Growth Rate (%)
2018	750	-
2019	950	26.7%
2020	1,200	26.3%
2021	1,500	25%
2022	1,860	24%

Major growth driven by expanded indications and increased adoption.

3.2 Forecasted Sales (2023-2028)

Year	Projected Sales (USD millions)	Assumptions	Key Factors
2023	2,300	Continued market expansion	Entry into Asian markets, generic threat delaying current growth
2024	2,800	Patent exclusivity, increased prescriptions	Patent expiry on some competitor assets
2025	3,400	Market saturation, pipeline launches	Biosimilar competition in other inhalers
2026	4,200	Differentiation strategies, payer acceptance	New formulation approvals
2027	4,950	Peak market penetration	Patent cliffs approaching for competitors
2028	5,500	Stabilization as generics enter	Patent expirations dilute market share

3.3 Revenue Drivers & Risks

Drivers	Risks	Mitigation Strategies
Expanded indications	Patent expiry, generic competition	Patent extension filings, pipeline diversification
Geographic expansion	Regulatory hurdles, pricing pressures	Local market studies, strategic partnerships
Product lifecycle management	Market saturation	R&D for next-generation delivery systems

---

4. Patent & Regulatory Outlook

Patent Type	Expected Expiry	Key Protection	Strategy
Composition Patents	2028	Exclusive formulation rights	Filing continuation applications, formulation patents
Device Patents	2030	Inhaler device design	Innovation within inhaler technology
Method of Use	2025	Specific indications	Broadened indications for extended protection

Patent expirations could open opportunities for generics from 2024 onwards, impacting revenue streams.

---

5. Competitive Positioning and Strategic Opportunities

Strategy	Rationale	Source/Examples
Patent extension and formulation optimization	Extend exclusivity	GSK’s ongoing patent filings (2020-2022)
Pipeline diversification	Reduce dependence on FF/VI	Development of triple therapies and biologics
Geographic expansion	Tap into emerging markets	Asian and Latin American regulatory approvals underway
Digital health integration	Enhance adherence	Embedding smart inhaler tech; partnerships with digital firms

---

6. Investment Considerations and Valuation

Valuation Metrics	2022 Data	2023-2028 Projections	Remarks
Market Share	Estimated 10% in inhaler segment	Increase to 15–20%	Driven by patent life extension efforts
Sales CAGR	25% (2019-2022)	20% (2023-2028)	Market growth + market share gains
Market Cap (if publicly traded)	USD 15 billion (GSK Respiratory portfolio)	Potential to reach USD 25-30 billion	Based on sales growth and pipeline success
Investment Risks	Patent cliffs, regulatory delays, generic competition	Diversification of portfolio and R&D pipeline	Critical for valuation stability

---

7. Deep-Dive Comparison: FF/VI Vs. Competitor Combinations

| Attribute | FF/VI (Relvar/Trelegy Ellipta) | Advair, Symbicort | Braitreat, Spiriva | |--------------|------------------------------|------------------|----------------—| | Dosing Frequency | Once daily | Twice daily | Once daily | | Indications | Asthma, COPD | Asthma, COPD | COPD | | Patent Life Remaining | 2028 | 2024-2028 | 2025 | | Market Penetration | Moderate | High | Established in COPD | | Price Point | Premium | Premium | Competitive |

FF/VI’s once-daily dosing confers adherence advantages.

---

8. FAQs

Q1: What are the main growth drivers for Fluticasone Furoate / Vilanterol Trifenatate?

A: The primary drivers include expanding prevalence of asthma and COPD globally, increased adoption of once-daily inhalers improving patient adherence, pipeline expansion into new indications, and geographic expansion into untapped emerging markets.

Q2: How does patent expiry influence the product’s financial outlook?

A: Patent expiries, projected around 2028 for core formulations, signal potential entry of generic competitors, which could significantly decrease revenue. Strategic patent extensions, formulation innovations, and pipeline development are critical to maintaining competitive advantage.

Q3: What commercial strategies can sustain profitability despite patent expirations?

A: Strategies include developing next-generation formulations, expanding indications, engaging in pipeline diversification, leveraging digital health integrations, and expanding into emerging markets with localized regulatory approval.

Q4: What is the impact of competing combination inhalers, such as Advair or Symbicort?

A: While Advair and Symbicort hold substantial market share, FF/VI’s once-daily dosing and superior efficacy provide competitive differentiation. Continuous innovation and patent protection are necessary to maintain market share.

Q5: How do regulatory policies influence market entry for new formulations or generics?

A: Regulatory agencies enforce approvals based on safety and efficacy. Patent protections, regulatory exclusivities, and local approval processes can delay generic entry. Policy shifts toward biosimilars and generics can accelerate competition post-exclusivity.

---

Conclusion: Key Takeaways

• Strong Market Fundamentals: The global respiratory market is positioned for steady growth, driven by rising disease prevalence and modern therapeutic approaches.
• Patent Lifecycles: Core patents for FF/VI extend until 2028; strategic patent filings and formulation innovations are vital to prolong exclusivity.
• Growth Opportunities: Expanding indications, emerging markets, and improved adherence via device innovation are key levers.
• Competitive Landscape: Dominance by GSK with significant patent protection contrasts with subsequent patent cliffs and generic threats.
• Financial Outlook: Projected sales growth remains robust, with potential to reach USD 5.5 billion by 2028, contingent on patent management and pipeline success.
• Risk Management: Patent expirations, regulatory delays, and competitive launches require strategic planning and diversification.

---

References

1. Global Respiratory Disease Market Report, Markets and Markets, 2022.
2. GSK Annual Reports, 2018–2022.
3. FDA and EMA approval documents for FF/VI, 2013–2016.
4. Patent databases and filings, European Patent Office, 2022.
5. Investment analysis reports, IQVIA, 2022.